#uspharma
Anxiety medication Xanax recalled across US after quality issue
A nationwide recall has been issued for a specific lot of the widely prescribed anxiety medication Xanax after federal regulators identified a potential quality issue that could affect how the drug performs in patients. According to the U.S. Food and Drug Administration, pharmaceutical company Viatris initiated a voluntary recall on Monday, March 17, 2025. The recall involves one lot of extended-release tablets that failed to meet required dissolution specifications, a standa
Anxiety medication Xanax recalled across US after quality issue
A nationwide recall has been issued for a specific lot of the widely prescribed anxiety medication Xanax after federal regulators identified a potential quality issue that could affect how the drug performs in patients. According to the U.S. Food and Drug Administration, pharmaceutical company Viatris initiated a voluntary recall on Monday, March 17, 2025. The recall involves one lot of extended-release tablets that failed to meet required dissolution specifications, a standa
Trump announces 100 percent tariffs on branded drugs, India pharma may face big hit
Washington: US President Donald Trump has announced sweeping new tariffs on imported pharmaceutical products, a move that could trigger widespread consequences for the global drug trade and India’s pharmaceutical sector in particular. Effective October 1, 2025, Washington will impose tariffs of up to 100 percent on branded and patented pharmaceutical drugs unless the manufacturing companies are building their production facilities within the United States. The president emphasized that
Trump announces 100 percent tariffs on branded drugs, India pharma may face big hit
Washington: US President Donald Trump has announced sweeping new tariffs on imported pharmaceutical products, a move that could trigger widespread consequences for the global drug trade and India’s pharmaceutical sector in particular. Effective October 1, 2025, Washington will impose tariffs of up to 100 percent on branded and patented pharmaceutical drugs unless the manufacturing companies are building their production facilities within the United States. The president emphasized that









